Upstream Bio, Inc. Income Statement
UPB / Health Care|2 years of annual SEC 10-K data (FY2023-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$2M
FY2024
Gross Profit
N/A
FY2024
Operating Income
-$78M
FY2024
Net Income
-$63M
FY2024
Upstream Bio, Inc. reported $2M in revenue and $63M in net loss for FY2024. Revenue decreased 0.4% from FY2023 to FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 |
|---|---|---|
| Revenue | $2.4M | $2.4M |
| SG&A Expense | $17.2M | $10.7M |
| R&D Expense | $63.0M | $31.8M |
| Operating Income | -$77.8M | -$40.1M |
| Income Tax | $0 | $0 |
| Net Income | -$62.8M | -$20.5M |
| EPS (Basic) | -$5.58 | -$12.95 |
| EPS (Diluted) | -$5.58 | -$12.95 |
| Shares Outstanding | 13.7M | 3.0M |